CNS Drugs

, Volume 5, Issue 1, pp 37–50

Psychotropic Drug-Induced Reductions in Seizure Threshold

Incidence and Consequences
  • Glen L. Stimmel
  • Julie A. Dopheide
Adverse Effects Psychotropic Drug-Induced Seizures

Abstract

Summary

There are no simple answers to questions such as ‘Which antidepressant is most likely to cause seizures?’ or ‘Which antipsychotic drug is the safest to use in a patient with a seizure disorder?’

The risk of psychotropic drug-induced seizures is dependent on many factors beyond inherent differences in the propensity of individual drugs to lower seizure threshold. Individual patient variables that affect the likelihood of drug-induced seizures occurring include a history of epilepsy or seizures, a family history of epilepsy, and postnatal brain damage, head trauma and dementia. Once a drug is selected, seizure risk is directly dependent on dosage, rate and amount of dose titration, and concurrent use of other drugs.

Setting aside these other risk factors, the likelihood of drug-induced seizures occurring does differ among psychotropic drugs. Among antipsychotic drugs, clozapine is associated with the highest risk of seizures, followed by chlorpromazine, with other phenothiazines and risperidone having a lower risk and haloperidol the least risk.

Among antidepressants, maprotiline, amoxapine, amfebutamone (bupropion) and clomipramine pose the greatest risk along with other tricyclic antidepressants in high doses. Monoamine oxidase inhibitors (MAOIs), trazodone, nefazodone and the selective serotonin (5-hydroxytryptamine; 5-HT) reuptake inhibitors (SSRIs) are associated with a lower risk of seizures.

Benzodiazepines with long elimination half-lives are less likely to cause seizures during withdrawal than those agents with short to intermediate half-lives, although the rate and amount of dosage reduction are more important variables.

Finally, most psychotropic drugs are metabolised by cytochrome P450 isoenzymes. Concurrent use of enzyme inhibitors or discontinuation of enzyme inducers may cause a significant increase in plasma concentrations of the psychotropic drug, increasing the likelihood of adverse effects and the potential for seizures.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Rosenstein DL, Nelson JC, Jacons Sc. Seizures associated with antidepressants: a review. J Clin Psychiatry 1993; 54: 289–99PubMedGoogle Scholar
  2. 2.
    Skowron OM, Stimmel GL. Antidepressants and the risk of seizures. Pharmacotherapy 1992; 12: 18–22PubMedGoogle Scholar
  3. 3.
    Davidson J. Seizures and bupropion: a review. J Clin Psychiatry 1989; 50: 256–61PubMedGoogle Scholar
  4. 4.
    Schaul N, DeGreef G, Ney GC. Psychotropic drugs and seizures. In: Kane JM, Lieberman JA, editors. Adverse effects of psychotropic drugs. New York: Guilford Press, 1992: 321–37Google Scholar
  5. 5.
    Cold JA, Wells BG, Froemming JH. Seizure activity associated with antipsychotic therapy. DICP 1990; 24: 601–6PubMedGoogle Scholar
  6. 6.
    Small JG, Milstein V, Small IF, et al. Computerized EEG profiles of haloperidol, chlorpromazine, c1ozapine, and placebo in treatment resistant schizophrenia. Clin Electroencephalogr 1987; 18: 124–35PubMedGoogle Scholar
  7. 7.
    Trimble M. The relationship between epilepsy and schizophrenia: a biochemical hypothesis. Biol Psychiatry 1977; 12: 299–304PubMedGoogle Scholar
  8. 8.
    Olson KR, Kearney TE, Dyer JE, et al. Seizures associated with poisoning and drug overdose. Am J Emerg Med 1993; 11: 565–8PubMedCrossRefGoogle Scholar
  9. 9.
    Spontaneous epileptic seizures and electroencephalographic changes in the course of phenothiazine therapy. Neurology 1967; 17: 869–77Google Scholar
  10. 10.
    Hil TM, Soldatos C. Epileptogenic side effects of psychotropic drugs. JAMA 1980; 244: 1460–3CrossRefGoogle Scholar
  11. 11.
    Kurtzke JE. Seizures with promazine, preliminary report. J Nerv Ment Dis 1957; 125: 119–25PubMedCrossRefGoogle Scholar
  12. 12.
    Prien RF, Cole JO. High dose chlorpromazine therapy in chronic schizophrenia. Arch Gen Psychiatry 1968; 18: 482–95CrossRefGoogle Scholar
  13. 13.
    Quitkin F, Rifkin A, Klein DE. Very high dosage versus standard dosage fluphenazine in schizophrenia. Arch Gen Psychiatry 1975; 32: 1276–81PubMedCrossRefGoogle Scholar
  14. 14.
    Remick RA, Fine SH. Antipsychotic drugs and seizures. J Clin Psychiatry 1979; 40: 78–80PubMedGoogle Scholar
  15. 15.
    Devinsky O, Honigfeld G, Patin J. Clozapine-related seizures. Neurology 1991; 41: 369–71PubMedCrossRefGoogle Scholar
  16. 16.
    Pacia SV, Devinsky O. Clozapine-related seizures. Neurology 1994; 44: 2247–9PubMedCrossRefGoogle Scholar
  17. 17.
    Welch J, Manschreck T, Redmond D. Clozapine-induced seizures and EEG changes. J Neuropsychiatry Clin Neurosci 1994; 6: 250–6PubMedGoogle Scholar
  18. 18.
    Gunther W, Baghai T, Naber O, et al. EEG alterations and seizures during treatment with c1ozapine. Pharmacopsychiatry 1993; 26: 69–74PubMedCrossRefGoogle Scholar
  19. 19.
    Tiihonen J, Nousiainen U, Hakola P, et al. EEG abnormalities associated with c10zapine treatment [letter). Am J Psychiatry 1991; 148: 1406PubMedGoogle Scholar
  20. 20.
    Liukkonen J, Koponen HJ, Nousiainen U. Clinical picture and longterm course of epileptic seizures that occur during c1ozapine treatment. Psychiatry Res 1992; 44: 107–12PubMedCrossRefGoogle Scholar
  21. 21.
    McCarthy RH. Seizures following smoking cessation in a c10zapine responder. Pharmacopsychiatry 1994; 27: 210–1PubMedCrossRefGoogle Scholar
  22. 22.
    Funderburg LG, Vertrees JE, True JE, et al. Seizure following addition of erythromycin to c10zapine treatment [letter]. Am J Psychiatry 1994; 151: 1840–1PubMedGoogle Scholar
  23. 23.
    Centorrino F, Baldessarini RJ, Kando J, et al. Serum concentrations of c10zapine and its major metabolites: effects of cotreatrnent with fluoxetine or valproate. Am J Psychiatry 1994; 151: 123–5PubMedGoogle Scholar
  24. 24.
    Wilson WH, Claussen AM. Seizures associated with c10zapine treatment in a state hospital. J Clin Psychiatry 1994; 55: 184–8PubMedGoogle Scholar
  25. 25.
    Devinsky O, Pacia SV. Seizures during c10zapine therapy. J Clin Psychiatry 1994; 55 (9) Suppl.B: 153–6PubMedGoogle Scholar
  26. 26.
    Kando JC, Tohen M, Castillo J, et al. Concurrent use of c1ozapine and valproate in affective and psychotic disorders. J Clin Psychiatry 1994; 55: 255–7PubMedGoogle Scholar
  27. 27.
    Wilson WH. Do anticonvulsants hinder clozapine treatment? Biol Psychiatry 1995; 37: 132–3PubMedCrossRefGoogle Scholar
  28. 28.
    Finley P, Warner D. Potential impact of valproic acid therapy on clozapine disposition. Biol Psychiatry 1994; 36: 487–8PubMedCrossRefGoogle Scholar
  29. 29.
    Cohen LJ. Risperidone. Pharmacotherapy 1994; 14: 253–65PubMedGoogle Scholar
  30. 30.
    Janssen Pharmaceutica. Risperdal package insert. Aug, 1994Google Scholar
  31. 31.
    Jabbari B, Bryan GE, March EE, et al. Incidence of seizures with tricyclic and tetracyclic antidepressants. Arch Neurol 1985; 42: 480–1PubMedCrossRefGoogle Scholar
  32. 32.
    Peck AW, Stem WC, Watkinson C. Incidence of seizures during treatment with tricyclic antidepressant drugs and bupropion. J Clin Psychiatry 1983; 44 (5Pt2): 197–201PubMedGoogle Scholar
  33. 33.
    Jick H, Dinan BJ, Hunter JR, et al. Tricyclic antidepressants and convulsions. J Clin Psychopharmacol 1983; 3: 182–5PubMedCrossRefGoogle Scholar
  34. 34.
    Preskorn SH, Fast GA. Tricyclic antidepressant-induced seizures and plasma drug concentration. J Clin Psychiatry 1992; 53: 160–2PubMedGoogle Scholar
  35. 35.
    Forstl H, Pohlmann-Eden B. Monitoring antidepressant-induced cerebral hyperexcitability [letter]. J Clin Psychiatry 1993; 54: 201PubMedGoogle Scholar
  36. 36.
    Ojemann LM, Friel PN, Trejo WJ, et al. Effect of doxepin on seizure frequency in depressed epileptic patients. Neurology 1983; 33: 646–8PubMedCrossRefGoogle Scholar
  37. 37.
    Wroblewski BA, McColgan K, Smith K, et al. The incidence of seizures during tricyclic antidepressant drug treatment in a brain-injured population. J Clin Psychopharmacol 1990; 10: 124–8PubMedCrossRefGoogle Scholar
  38. 38.
    Hulten BA, Heath A. Clinical aspects of tricyclic antidepressant poisoning. Acta Med Scand 1983; 213: 275–8PubMedCrossRefGoogle Scholar
  39. 39.
    Lavoie FW, Gansert GG, Weiss RE. Value of initial ECG findings and plasma drug levels in cyclic antidepressant overdose. Ann Emerg Med 1990; 19: 696–700PubMedCrossRefGoogle Scholar
  40. 40.
    DeVeaugh-Geis J, Landau P, Katz R. Preliminary results from a multicenter trial of clomipramine in obsessive-compulsive disorder. Psychopharmacol Bull 1989; 25: 36–40Google Scholar
  41. 41.
    Jermain DM, Crismon ML. Pharmacotherapy of obsessivecompulsive disorder. Pharmacotherapy 1990; 10: 175–98PubMedGoogle Scholar
  42. 42.
    Pascual J, Combarros O, Berciano J. Partial status epileptic us following single low dose of chlorimipramine in a patient on MAO inhibitor treatment. Clin Neuropharmacol 1987; 10: 565–7PubMedCrossRefGoogle Scholar
  43. 43.
    Jick SS, Jick H, Knauss TA, et al. Antidepressants and convulsions. J Clin Psychopharmacol 1992; 12: 241–5PubMedCrossRefGoogle Scholar
  44. 44.
    Buckley NA, Dawson AH, Whyte JM, et al. Greater toxicity in overdose of dothiepin than of other tricyclic antidepressants. Lancet 1994; 343: 159–62PubMedCrossRefGoogle Scholar
  45. 45.
    Dessain EC, Schatzberg AF, Woods BT, et al. Maprotiline treatment in depression. Arch Gen Psychiatry 1986; 43: 86–90PubMedCrossRefGoogle Scholar
  46. 46.
    Knudsen K, Heath A. Effects of self poisoning with maprotiline. BMJ 1984; 288: 601–3PubMedCrossRefGoogle Scholar
  47. 47.
    Wyss PA, Serena S, Meier PJ. Dose-dependency of seizures in maprotiline (Ludiomil) intoxications [abstract]. Vet Hum Toxicol 1993; 35: 341Google Scholar
  48. 48.
    Smith RS, Ayd FJ. A critical appraisal of amoxapine. J Clin Psychiatry 1981; 42: 238–42PubMedGoogle Scholar
  49. 49.
    Litovitz TL, Troutman WG. Amoxapine overdose. JAMA 1983; 250: 1069–71PubMedCrossRefGoogle Scholar
  50. 50.
    Home RL, Ferguson JM, Pope HG, et al. Treatment of bulimia with bupropion: a multicenter controlled trial. J Clin Psychiatry 1988; 49: 262–6Google Scholar
  51. 51.
    Johnston JA, Lineberry CG, Ascher JA, et al. A 102-center prospective study of seizure in association with bupropion. J Clin Psychiatry 1991; 52: 450–6PubMedGoogle Scholar
  52. 52.
    Weber JJ. Seizure activity associated with fluoxetine therapy. Clin Pharm 1989; 8: 296–8PubMedGoogle Scholar
  53. 53.
    Messiha FS. Fluoxetine: adverse effects and drug-drug interactions. Clin Toxicol 1993; 31: 603–30CrossRefGoogle Scholar
  54. 54.
    Grady TA, Pigott TA, L’Heureux F, et al. Seizure associated with fluoxetine and adjuvant buspirone therapy [letter]. J Clin Psychopharmacol 1992; 12: 70–1PubMedCrossRefGoogle Scholar
  55. 55.
    Levine R, Kenin M, Hoffman JS, et al. Grand mal seizures associated with use of fluoxetine [letter]. J Clin Psychopharmacol 1994; 14: 145–6PubMedCrossRefGoogle Scholar
  56. 56.
    Braitberg G, Curry Sc. Seizure after isolated fluoxetine overdose. Ann Emerg Med 1992; 26: 234–7CrossRefGoogle Scholar
  57. 57.
    Myers LB, Dean BS, Krenzolok EP. Sertraline (Zoloft): overdose assessment of a new antidepressant [abstract]. Vet Hum Toxicol 1993; 35: 341Google Scholar
  58. 58.
    Boyer WF, Blumhardt CL. The safety profile of paroxetine. J Clin Psychiatry 1992; 53 Suppl.2: 61–6PubMedGoogle Scholar
  59. 59.
    Wagner W, Plekkenpol B, Gray TE, et al. Review of fluvoxamine safety database. Drugs 1992; 43 Suppl.2: 48–54PubMedCrossRefGoogle Scholar
  60. 60.
    Palmer KJ, Benfield P. Fluvoxamine: an overview of its pharmacological properties and a review of its use in non-depressive disorders. CNS Drugs 1994; 1: 57–87CrossRefGoogle Scholar
  61. 61.
    Spina E, Campo GM, Avenoso A, et al. Interaction between fluvoxamine and imipramine/desipramine in four patients. Ther Drug Monit 1992; 14: 194–6PubMedCrossRefGoogle Scholar
  62. 62.
    Preskorn SH. Recent pharmacologic advances in antidepressant therapy for the elderly. Am J Med 1993; 94 Suppl. 5A: 2S–12SPubMedGoogle Scholar
  63. 63.
    Sternbach H. Fluoxetine-clomipramine interaction [letter]. J Clin Psychiatry 1995; 56: 171–2PubMedGoogle Scholar
  64. 64.
    Tasini M. Complex partial seizures in a patient receiving trazodone. J Clin Psychiatry 1986; 47: 318–9PubMedGoogle Scholar
  65. 65.
    Balestrieri G, Cerudelli B, Ciaccio S, et al. Hyponatremia and seizure due to overdose of trazodone [letter]. BMJ 1992; 304: 686PubMedCrossRefGoogle Scholar
  66. 66.
    Gamble DE, Peterson LG. Trazodone overdose: four years of experience from voluntary reports. J Clin Psychiatry 1986; 47: 544–6PubMedGoogle Scholar
  67. 67.
    Bristol-Myers Squibb Company. Serzone package insert. Jan, 1995Google Scholar
  68. 68.
    Henry JA, Martin AJ. The risk-benefit assessment of antidepressant drugs. Med Toxicol 1987; 2: 445–62Google Scholar
  69. 69.
    Rabkin J, Quitkin F, Harrison W, et al. Adverse reactions to monoamine oxidase inhibitors. Part I: a comparative study. J Clin Psychopharmacol 1984; 4: 270–8PubMedCrossRefGoogle Scholar
  70. 70.
    Lieberman JA, Kane JM, Reife R. Neuromuscular effects of monoamine oxidase inhibitors. J Clin Psychopharmacol 1985; 5: 221–8PubMedCrossRefGoogle Scholar
  71. 71.
    Sternbach H. The serotonin syndrome. Am J Psychiatry 1991; 148: 705–13PubMedGoogle Scholar
  72. 72.
    Moll E, Hetzel W. Moclobemide (Ro 11-1163) safety in depressed patients. Acta Psychiatr Scand 1990; 90 Suppl.360: 69–70CrossRefGoogle Scholar
  73. 73.
    Freeman H. Moclobemide. Lancet 1993; 342: 1528–32PubMedCrossRefGoogle Scholar
  74. 74.
    Zaccara G, Muscas GC, Messori A. Clinical features, pathogenesis and management of drug-induced seizures. Drug Saf 1990; 5: 109–51PubMedCrossRefGoogle Scholar
  75. 75.
    Spiller HA, Krenzelok EP, Cookson E. Carbamazepine overdose: a prospective study of serum levels and toxicity. Clin Toxicol 1990; 28 (4): 445–58CrossRefGoogle Scholar
  76. 76.
    Small JG, Milstein V. Lithium interactions: lithium and electroconvulsive therapy. J Clin Psychopharmacol 1990; 10 (5): 346–50PubMedCrossRefGoogle Scholar
  77. 77.
    Seymour JF. Carbamazepine overdose: features of 33 cases. Drug Saf 1993; 8 (1): 81–8PubMedCrossRefGoogle Scholar
  78. 78.
    Malow BA, Blaxton TA, Stertz B, et al. Carbamazepine withdrawal: effects of taper rate on seizure frequency. Neurology 1993; 43: 2280–4PubMedCrossRefGoogle Scholar
  79. 79.
    Stoll AL, Banov M, Kolbrener M, et al. Neurologic factors predict a favorable response in bipolar and schizoaffective disorders. J Clin Psychopharmacol 1994; 14(5): 311–3PubMedCrossRefGoogle Scholar
  80. 80.
    Hollister LE. Pharmacology and pharmacokinetics of minor tranquilizers. Psychiatr Ann 1981; 11Suppl.: 26–31Google Scholar
  81. 81.
    Perry PJ. Assessment of addiction liability of benzodiazepines and buspirone. Drug Intell Clin Pharrn 1985; 19: 657–9Google Scholar
  82. 82.
    Warner MD, Peabody CA, Bouros NN. Alprazolam and withdrawal seizures. J Nerv Ment Dis 1990; 178 (3): 208–9PubMedCrossRefGoogle Scholar
  83. 83.
    Hollister LE, Muller-Oerlinghausen B, Rickels K, et al. Clinical uses ofbenzodiazepines. J Clin Psychopharmacol 1993; 13 (6 Suppl.1): 1S–161SPubMedGoogle Scholar
  84. 84.
    Sugai K. Seizures with clonazepam: discontinuation and suggestions for safe discontinuation rates in children. Epilepsia 1993; 34 (6): 1089–97PubMedCrossRefGoogle Scholar
  85. 85.
    Spivey WH. Flumazenil and seizures: analysis of 43 cases. Clin Ther 1992; 14 (2): 292–305PubMedGoogle Scholar
  86. 86.
    Haverkos GP, DiSalvo RP, Imhoff TE. Fatal seizures after flumazenil administration in a patient with mixed overdose. Ann Pharmacother 1994; 28: 1347–9PubMedGoogle Scholar
  87. 87.
    Greenberg DB. Buspirone for myoclonus, obsessive fears, and confusion. Psychosomatics 1993; 34 (3): 270–2PubMedCrossRefGoogle Scholar
  88. 88.
    Lowenstein DH, Massa SM, Rowbotham MC, et al. Acute neurologic and psychiatric complications associated with cocaine abuse. Am J Med 1987; 83: 841–6PubMedCrossRefGoogle Scholar
  89. 89.
    Washton AM, Tatarsky A. Adverse effects of cocaine abuse. In: Problems of drug dependence: NIDA Research Monograph Series 49. Washington (DC): US Department of Health and Human Services, 1983: 247–54Google Scholar
  90. 90.
    Alldredge BK, Lowenstein DH, Simon RP. Seizures associated with recreational drug abuse. Neurology 1989; 39: 1037–9PubMedCrossRefGoogle Scholar
  91. 91.
    Sands BF, Ciraulo DA. Cocaine drug-drug interactions. J Clin Psychopharmacol 1992; 12 (6): 445–7CrossRefGoogle Scholar
  92. 92.
    Holland RW, Marx JA, Earnest MP, et al. Grand mal seizures temporally related to cocaine use: clinical and diagnostic features. Ann Emerg Med 1992; 21: 772–6PubMedCrossRefGoogle Scholar
  93. 93.
    Dhuna A, Pascual-Leone A. New onset seizures after first-time cocaine abuse. Epilepsia 1990; 31 (5): 605–6Google Scholar
  94. 94.
    Skolnick A. Cocaine use in pregnancy: physicians urged to look for problem where they least expect it. JAMA 1990; 264 (3): 306–8PubMedCrossRefGoogle Scholar
  95. 95.
    Wroblewski BA, Leary JM, Phelan AM, et al. Methylphenidate and seizure frequency in brain injured patients with seizure disorders. J Clin Psychiatry 1992; 53: 86–9PubMedGoogle Scholar
  96. 96.
    Meisel SB, Welford PK. Seizures associated with high-dose intravenous morphine containing sodium bisulfite preservative. Ann Pharmacother 1992; 26: 1515–7PubMedGoogle Scholar
  97. 97.
    Parkinson SK, Bailey SL. Myoclonic seizure activity with chronic high-dose spinal opioid administration. Anesthesiology 1990; 72: 743–5PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1996

Authors and Affiliations

  • Glen L. Stimmel
    • 1
  • Julie A. Dopheide
    • 2
  1. 1.Psychiatry and the Behavioural SciencesUniversity of Southern California Schools of Pharmacy and MedicineLos AngelesUSA
  2. 2.University of Southern California School of PharmacyLos AngelesUSA

Personalised recommendations